课题基金 / 基金详情

Side effect-free cathepsin K targeting drugs for skeletal diseases

Side effect-free cathepsin K targeting drugs for skeletal diseases
用于骨骼疾病的无副作用组织蛋白酶 K 靶向药物
批准号:
523434-2018
负责人:
Bromme, Dieter
金额:
$8.88万
依托单位国家:
加拿大
项目类别:
Collaborative Health Research Projects
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-01-01 至 2019-12-31

项目摘要

项目成果

Bromme, Dieter的其他基金

相似基金

相关文献

中文摘要
翻译
关节炎疾病影响15%的人口,骨癌是最常见的乳腺癌和前列腺癌的常见转移性副作用。除了人类的痛苦之外,治疗这些疾病还增加了巨大的医疗保健费用。目前的治疗方法有各种缺点和副作用,包括增加癌症风险,非典型骨折,骨坏死,感染和血管问题。显然需要更有效、更安全的治疗方法。不幸的是,近年来进展甚微。大多数治疗攻击非特异性的整个细胞或阻断复杂的途径,这可能导致副作用。相比之下,蛋白酶,组织蛋白酶K,是唯一负责 ** 骨降解和显着有助于关节侵蚀。它的抑制作用已被证明能有效降低绝经后妇女的骨折率。然而,这种 ** 治疗也有严重的副作用,导致 ** 组织蛋白酶K抑制剂的进一步发展终止。我们的研究已经确定并验证了一种新型的组织蛋白酶K** 抑制剂,而不会引起临床试验中观察到的任何副作用。有趣的是,这些化合物的主要来源是传统上用于骨骼疾病的某些中草药。最近,我们已经在骨质疏松症模型 ** 中显示了这些化合物之一的功效,而没有任何可观察到的副作用。该项目将扩展这种方法,并将从草药化合物中产生更有效和更可药用的衍生物。将在关节炎和骨癌小鼠模型中分析化合物。我们预期这些化合物将 ** 具有上级功效,并且没有或比当前治疗方案更少的副作用。这个项目需要化学家、制药科学家、生物化学家和动物模型研究人员之间强有力的跨学科合作,并将为学生的培训提供一个极好的机会。
英文摘要
Arthritic diseases affect 15 % of the population and bone cancer is a frequent metastatic side**effect of the most common breast and prostate cancer. Aside from human suffering enormous**financial health care costs are added to the treatment of these diseases. Current treatments**have various shortcomings and side effects, which include increased cancer risks, atypical**fractures, bone necrosis, infections, and vascular problems. There is clearly a need for more**effective and safer treatments. Unfortunately, little progress has been made in recent years.**Most treatments attack rather non-specifically entire cells or block complex pathways, which**is likely causing the side effects. In contrast, the protease, cathepsin K, is solely responsible**for the bone degradation and significantly contributes to joint erosion. Its inhibition has been**shown to effectively reduce fracture rates in post-menopausal women. However, this**treatment also had severe side effects leading to the termination of the further development of**cathepsin K inhibitors. Our research has identified and verified a novel type of cathepsin K**inhibitors without causing any of the side effects seen in clinical trials. Interestingly, a major**source of these compounds are certain Chinese herbs traditionally used in skeletal diseases.**Recently, we have shown the efficacy of one of these compounds in an osteoporosis model**without any observable side effects. This project will expand this approach and will generate**more potent and druggable derivatives from the herbal compounds. Compounds will be**analyzed in arthritis and bone cancer mouse models. We anticipate that these compounds will**have a superior efficacy with no or fewer side effects than current treatment regimes. This**project requires a strong interdisciplinary collaboration between chemists, pharmaceutical**scientists, biochemists, and animal model researchers and will provide an excellent**opportunity for the training of students.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The ligase activity of proteases: Do proteases make proteins?
  • 批准号:
    RGPIN-2019-06720
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.62万
  • 财政年份:
    2022
  • 负责人:
    Bromme, Dieter
  • 依托单位:
The ligase activity of proteases: Do proteases make proteins?
  • 批准号:
    RGPIN-2019-06720
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.62万
  • 财政年份:
    2021
  • 负责人:
    Bromme, Dieter
  • 依托单位:
The ligase activity of proteases: Do proteases make proteins?
  • 批准号:
    RGPIN-2019-06720
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $2.62万
  • 财政年份:
    2020
  • 负责人:
    Bromme, Dieter
  • 依托单位:
Side effect-free cathepsin K targeting drugs for skeletal diseases
  • 批准号:
    523434-2018
  • 项目类别:
    Collaborative Health Research Projects
  • 资助金额:
    $17.34万
  • 财政年份:
    2019
  • 负责人:
    Bromme, Dieter
  • 依托单位:
国内基金
海外基金
Crocin 抑制 Hartley 豚鼠早期骨关节炎发生的 作用机制研究
超声驱动压电效应激活门控离子通道促眼眶膜内成骨的作用及机制研究
  • 批准号:
    82371103
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    阮静
  • 依托单位:
LINC00673调控HIF-1α促进Warburg effect在子宫内膜蜕膜化中的作用和机制研究
  • 批准号:
    82060281
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    34.0万元
  • 批准年份:
    2020
  • 负责人:
    朱元昌
  • 依托单位:
PKM2调控H2B泛素化修饰的分子机制及其在肿瘤代谢中的作用研究
  • 批准号:
    81773009
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2017
  • 负责人:
    陈苏
  • 依托单位: